Recent Security Class Actions

Amylyx Pharmaceuticals Inc. Common Stock (NASDAQ: AMLX)

Company Name:Amylyx Pharmaceuticals Inc. Common Stock
Stock Symbol:NASDAQ: AMLX
Class Period Start:11/11/2022
Class Period End (inclusive):11/08/2023
Filing Deadline:04/09/2024

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated the commercial prospects of its product, RELYVRIO, a treatment used for ALS; (ii) patients were discontinuing RELYVRIO treatment after six months; (iii) the rate at which new patients were starting treatment with RELYVRIO was decreasing; (iv) the Company had also overstated RELYVRIO's prescription rate; (v) the Company attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing its prescription data; and (vi) as a result of the foregoing, the Company’s financial statements were materially false and misleading at all relevant times.